# The Possible Efficacy and Protective Effect of Empagliflozin in Rheumatoid Arthritis Patients Treated with Methotrexate

> **NCT06641128** · PHASE4 · NOT_YET_RECRUITING · sponsor: **Tanta University** · enrollment: 44 (estimated)

## Conditions studied

- Rheumatoid Arthritis (RA)
- Methotrexate Induced Nephrotoxicity
- Methotrexate Adverse Reaction

## Interventions

- **DRUG:** MTX SC or IM
- **DRUG:** Empagliflozin 25mg tab

## Key facts

- **NCT ID:** NCT06641128
- **Lead sponsor:** Tanta University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-10-15
- **Primary completion:** 2025-03-10
- **Final completion:** 2025-04-10
- **Target enrollment:** 44 (ESTIMATED)
- **Last updated:** 2024-10-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06641128

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06641128, "The Possible Efficacy and Protective Effect of Empagliflozin in Rheumatoid Arthritis Patients Treated with Methotrexate". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06641128. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*